Detail akcie NovaBay Pharma Rg online

Business Summary: NovaBay Pharmaceuticals, Inc. is engaged in wound care products. The Company manufactures and sells its proprietary form of hypochlorous acid for the wound care market through its NeutroPhase and PhaseOne branded products. NeutroPhase and PhaseOne are used for cleansing and irrigation as part of surgical procedures, as well as treating wounds, burns, ulcers and other injuries.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, NovaBay Pharmaceuticals Inc revenues decreased 78% to $521K. Net loss applicable to common stockholders excluding extraordinary items decreased 14% to $6.6M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Basic Earnings per Share excluding Extraordinary Items increased from -$31.39 to -$1.19.